Equities analysts expect that Genomic Health, Inc. (NASDAQ:GHDX) will announce earnings of $0.29 per share for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Genomic Health’s earnings. The lowest EPS estimate is $0.26 and the highest is $0.30. Genomic Health posted earnings of $0.13 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 123.1%. The firm is scheduled to announce its next earnings results on Wednesday, May 1st.

On average, analysts expect that Genomic Health will report full-year earnings of $1.49 per share for the current financial year, with EPS estimates ranging from $1.42 to $1.54. For the next fiscal year, analysts forecast that the business will report earnings of $1.67 per share, with EPS estimates ranging from $1.43 to $1.85. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Genomic Health.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Wednesday, February 20th. The medical research company reported $0.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.02. The business had revenue of $104.56 million during the quarter, compared to the consensus estimate of $101.55 million. Genomic Health had a net margin of 6.52% and a return on equity of 16.86%. Genomic Health’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 earnings per share.

A number of research analysts recently issued reports on GHDX shares. BidaskClub upgraded shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 9th. Needham & Company LLC assumed coverage on shares of Genomic Health in a report on Wednesday, January 2nd. They set a “strong-buy” rating and a $86.00 price objective for the company. Piper Jaffray Companies upped their price target on shares of Genomic Health to $86.00 and gave the company a “neutral” rating in a report on Thursday, February 21st. Finally, ValuEngine cut shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a report on Tuesday, March 5th. Ten analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Genomic Health has a consensus rating of “Hold” and an average target price of $63.13.

In other news, Director Bros. Advisors Lp Baker sold 600 shares of the business’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $76.20, for a total value of $45,720.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO G Bradley Cole sold 15,000 shares of the business’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $67.61, for a total transaction of $1,014,150.00. The disclosure for this sale can be found here. In the last three months, insiders sold 2,246,252 shares of company stock worth $163,036,665. 45.80% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in GHDX. Wells Fargo & Company MN lifted its position in shares of Genomic Health by 3.7% in the third quarter. Wells Fargo & Company MN now owns 57,324 shares of the medical research company’s stock worth $4,025,000 after purchasing an additional 2,071 shares in the last quarter. JPMorgan Chase & Co. raised its position in Genomic Health by 15.2% during the third quarter. JPMorgan Chase & Co. now owns 6,145 shares of the medical research company’s stock worth $432,000 after acquiring an additional 813 shares in the last quarter. BlackRock Inc. raised its position in Genomic Health by 1.7% during the third quarter. BlackRock Inc. now owns 2,037,436 shares of the medical research company’s stock worth $143,070,000 after acquiring an additional 34,464 shares in the last quarter. FMR LLC raised its position in Genomic Health by 125.5% during the third quarter. FMR LLC now owns 299,542 shares of the medical research company’s stock worth $21,034,000 after acquiring an additional 166,681 shares in the last quarter. Finally, United Services Automobile Association bought a new stake in Genomic Health during the third quarter worth $440,000. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ GHDX opened at $61.93 on Monday. The company has a market cap of $2.29 billion, a P/E ratio of 58.98 and a beta of 0.95. Genomic Health has a 52-week low of $31.05 and a 52-week high of $92.18.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Read More: NASDAQ

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.